AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36096147
Drug: RTS,S/AS01E malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01E malaria vaccine
Trial: 33811730
Drug: Permanent polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permanent polymer zotarolimus-eluting stent (PP-ZES) in insulin-treated diabetics
Trial: 33811730
Drug: Polymer-free amphilimus-eluting
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymer-free amphilimus-eluting stent (PF-AES) in insulin-treated diabetics
Trial: 35123510
Drug: Macitentan treatment
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan treatment
Trial: 35543102
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg twice weekly for 16 weeks)
Trial: 33535474
Drug: BRAINballs program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRAINballs program (conducted twice a week)
Trial: 33218845
Drug: Biostimulant formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biostimulant formulation 2 at a dosage of 0.25 kg ha-1
Trial: 33218845
Drug: Biostimulant formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biostimulant formulations (F1, F2, F3) at dosages of 0.25, 0.50, and 1.0 kg ha-1
Trial: 39102111
Drug: Conventional diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional diet (0.8-1.0 g/kg/day of protein)
Trial: 35608270
Drug: 4 mg/ml
RxNorm normalized name: valine 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/ml dilution of vancomycin
Trial: 35608270
Drug: 20 mg/ml
RxNorm normalized name: urea 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/ml dilution of vancomycin
Trial: 33317565
Drug: Peanut protein
RxNorm normalized name: peanut protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut protein (PP) supplement (75 total g powder providing 30 g protein, >9.2 g essential amino acids, 315 kcal; n=20)
Trial: 33317565
Drug: Control (CTL;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (CTL; no supplement; n=19)
Trial: 33317565
Drug: Peanut protein
RxNorm normalized name: peanut protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut protein (PP) supplement
Trial: 33317565
Drug: Peanut protein
RxNorm normalized name: peanut protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut protein (PP) supplement (10-week group)
Trial: 33465382
Drug: Abdominal massage
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal massage using 'I LOV U' method along with lifestyle education, 15 min, twice daily for 10 days.
Trial: 34021915
Drug: IV dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV dexamethasone (2 mL, 8 mg)
Trial: 34021915
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL IV solution)
Trial: 32081056
Drug: Herbal combination
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal combination
Trial: 35944104
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia using propofol (Group T)
Trial: 35944104
Drug: Inhalation general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation general anesthesia using sevoflurane (Group I)
Trial: 32745732
Drug: Smartphone application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone application for medication adherence (6 months)
Trial: 33276251
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol MDI HFA (250 μg/50 μg, twice daily)
Trial: 33276251
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol DPI (500 μg/50 μg, twice daily)
Trial: 35544095
Drug: Dihydroartemisinin-piperaquine plus
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine plus tafenoquine 0.42 mg/kg
Trial: 35544095
Drug: Dihydroartemisinin-piperaquine plus
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine plus tafenoquine 0.83 mg/kg
Trial: 35544095
Drug: Dihydroartemisinin-piperaquine plus
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine plus tafenoquine 1.66 mg/kg
Trial: 35136296
Drug: Targeted fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted fluid therapy (Group-T)
Trial: 35136296
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid therapy (Group-S)
Trial: 32409830
Drug: Preoperative chemoradiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy
Trial: 32409830
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus adjuvant chemotherapy (standard treatment)
Trial: 32411431
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab injections
Trial: 34352146
Drug: MFU‐V combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFU‐V combined with L‐HA injection (combined technique)
Trial: 34352146
Drug: MFU‐V monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFU‐V monotherapy (single technique)
Trial: 32542370
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (200 mg Venofer® in 100 ml saline on days 1, 3, and 5)
Trial: 33208325
Drug: Zinc biofortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc biofortified wheat flour (target zinc concentration of 40 mg/kg)
Trial: 33208325
Drug: Locally procured
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally procured wheat flour from standard varieties (expected zinc concentration of 20 mg/kg)
Trial: 33648568
Drug: Dexamethasone 20
RxNorm normalized name: dexamethasone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 20 mg intravenously once daily on days 1-5, followed by 10 mg on days 6-10
Trial: 33648568
Drug: Dexamethasone 6
RxNorm normalized name: dexamethasone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 6 mg intravenously once daily on days 1-10
Trial: 35033182
Drug: Dexamethasone 20
RxNorm normalized name: dexamethasone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 20 mg
Trial: 35462372
Drug: Desidustat 100
RxNorm normalized name: Desidustat
DrugBank: Desidustat (DB16135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desidustat 100 mg oral tablets thrice a week for 24 weeks
Trial: 35462372
Drug: Biosimilar darbepoetin
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biosimilar darbepoetin subcutaneous injection 0.75 μg/kg once in 2 weeks for 24 weeks
Trial: 33580472
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids treatment for 16 weeks
Trial: 36447623
Drug: Immersive Virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive Virtual Reality (VR) therapy
Trial: 36447623
Drug: Standard neurological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard neurological rehabilitation + VR therapy
Trial: 34916467
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg rifampin
Trial: 34916467
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of rifampin
Trial: 36412403
Drug: Gemcitabine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (150 mg/m2 weekly)
Trial: 36412403
Drug: Cisplatin (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (35 mg/m2 weekly)
Trial: 32993388
Drug: Current pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current pharmacological treatments
Trial: 32993388
Drug: Emerging pharmacological
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging pharmacological treatments
Trial: 35550261
Drug: BNT162b2 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (30 μg in 0.30 mL; full dose)
Trial: 35550261
Drug: mRNA-1273 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (50 μg in 0.25 mL; half dose)
Trial: 32814500
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group watched the same video on a tablet once
Trial: 616120592
Drug: EBI‐005 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBI‐005 (5 or 20 mg/mL)
Trial: 35298522
Drug: Hot pack
RxNorm normalized name: cold-hot pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hot pack treatment
Trial: 34792290
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) sessions (n = 67)
Trial: 33227224
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) applied over 14 sites per lower limb immediately before 1500 m run, delivering 30 J per site, total energy dose of 840 J.
Trial: 34791771
Drug: Multi-plant extracts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-plant extracts product (oral intake for 12 weeks)
Trial: 34791771
Drug: UV+high dose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV+high dose group (0.500 g/kg.BW)
Trial: 34791771
Drug: UV+moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV+moderate dose group (0.250 g/kg.BW)
Trial: 34791771
Drug: UV+low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: UV+low dose group (0.125 g/kg.BW)
Trial: 34791771
Drug: UV+high and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV+high and moderate dose groups
Trial: 33780928
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL of water every 2 hours (1,600 mL per day)
Trial: 33780928
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of water every 2 hours (800 mL per day)
Trial: 33780928
Drug: 110 mL
RxNorm normalized name: IODINE 110 mL in 10 L TOPICAL LIQUID [BoviSoft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 110 mL of water every 1 hour (1,650 mL per day)
Trial: 32819928
Drug: ENACT (Environmental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENACT (Environmental enrichment for infants; parenting with Acceptance and Commitment Therapy)
Trial: 34873117
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy protocol based on physical exercise
Trial: 34873117
Drug: Hospital's physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital's physical therapy protocol
Trial: 35582999
Drug: Mometasone nasal
RxNorm normalized name: mometasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone nasal spray for four weeks (M)
Trial: 35582999
Drug: Mometasone nasal
RxNorm normalized name: mometasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone nasal spray plus oral commercially available quail egg and zinc tablets (M+N)
Trial: 35318738
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g rosemary leaf powder
Trial: 35107239
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) treatment for ovarian rejuvenation
Trial: 32306634
Drug: Noise-exposure +
RxNorm normalized name: Anthrax, post-exposure prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noise-exposure + doxycycline (50 mg/kg/d for 4 consecutive days)
Trial: 33028101
Drug: PZ‐128 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZ‐128 (0.3 or 0.5 mg/kg)
Trial: 33028101
Drug: PZ‐128 (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZ‐128 (combined doses)
Trial: 33208752
Drug: SAFER pregnancy
RxNorm normalized name: Safe-Guard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAFER pregnancy intervention (monthly group sessions, web-based platform, incentives for cessation)
Trial: 35121638
Drug: Electronic monitoring
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic monitoring feedback (EMF) with a Medication Event Monitoring System (MEMS) cap and motivational interviewing feedback.
Trial: 33560097
Drug: Micafungin 100
RxNorm normalized name: micafungin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 100 mg daily
Trial: 32529176
Drug: Needle-free insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Needle-free insulin injector (NFII)
Trial: 32529176
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin pen (CIP)
Trial: 32162352
Drug: Intravenous vitacoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitacoxib (0.1 mg/kg)
Trial: 32162352
Drug: Oral paste
RxNorm normalized name: Oral Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paste vitacoxib (0.1 mg/kg)
Trial: 32162352
Drug: Oral tablet
RxNorm normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet vitacoxib (0.1 mg/kg)
Trial: 36695682
Drug: Low-dose cholecalciferol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cholecalciferol
Trial: 35796481
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (3.3-3.9 g/day)
Trial: 34142950
Drug: Generic clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic clozapine (ChangZhou Pharmaceutical Factory Co. Ltd.) 100 mg twice daily for 10 days
Trial: 34142950
Drug: Clozaril (HLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozaril (HLS Therapeutics, Inc.) 100 mg twice daily for 10 days
Trial: 37130044
Drug: Riluzole treatment
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole treatment
Trial: 34706374
Drug: TEA1 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEA1 (1000 mL with approximately 200,000 µg silicon/L)
Trial: 34706374
Drug: TEA2 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEA2 (1000 mL with approximately 750,000 µg silicon/L)
Trial: 34706374
Drug: Si-low-Water (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Si-low-Water (approximately 10-10,000 µg silicon/L as a control)
Trial: 33451926
Drug: Alfaxalone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (15 mg kg−1) and midazolam (2 mg kg−1) with flumazenil (0.3 mg kg−1)
Trial: 33451926
Drug: Alfaxalone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (15 mg kg−1) and midazolam (2 mg kg−1) with saline
Trial: 32945236
Drug: Inappropriate time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate time of spray
Trial: 32945236
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of spray
Trial: 32945236
Drug: Long hours
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long hours of daily chemical spray
Trial: 32101915
Drug: Combination (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (group C)
Trial: 35109685
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (ΔSBP15-60M)
Trial: 35109685
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (ΔSBP6-24H)
Trial: 37638077
Drug: Inhaled methoxyflurane
RxNorm normalized name: methoxyflurane Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methoxyflurane 3 ml
Trial: 33676727
Drug: Fentanyl 25
RxNorm normalized name: FENTANYL 25MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 25 μg i.v.
Trial: 33676727
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 μg i.v.
Trial: 34698342
Drug: Free distribution
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free distribution of oral rehydration salts (ORS) via home deliveries prior to diarrhea onset
Trial: 33550193
Drug: Rosemary essential
RxNorm normalized name: EUCALYPTOL 2.4 g in 100 g TOPICAL LIQUID [MELAO ROSEMARY ESSENTIAL Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosemary essential oil inhalation (1 drop using a mask)
Trial: 35468032
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: misoprostol 400 mcg vaginally and pyridoxine 40 mg sublingually
Trial: 35468032
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: misoprostol 400 mcg sublingually and pyridoxine 40 mg vaginally
Trial: 33220066
Drug: High-dose flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose flumazenil (20 µg/kg)
Trial: 33220066
Drug: Low-dose flumazenil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose flumazenil (10 µg/kg)
Trial: 33529081
Drug: LEM5 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEM5 treatment (5 g lemongrass/ewe/d)
Trial: 33529081
Drug: LEM10 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEM10 treatment (10 g lemongrass/ewe/d)
Trial: 33529081
Drug: Control (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (without supplement)
Trial: 34848381
Drug: VP250 (250‐μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP250 (250‐μg peanut protein)
Trial: 34511891
Drug: Tiotropium/Olodaterol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium/Olodaterol (5 μg/5 μg)
Trial: 34189981
Drug: B12 fortified
RxNorm normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B12 fortified nutrient bar (2 μg)
Trial: 34189981
Drug: B12 fortified
RxNorm normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B12 fortified yogurt (2 μg)
Trial: 34189981
Drug: Propionibacterium (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionibacterium (1 × 10^8 cfu/g)
Trial: 33427870
Drug: Oral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin (400 mg/d for 7 days)
Trial: 33427870
Drug: Intravenous ertapenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ertapenem (1 g/d for 2 days) followed by oral levofloxacin (500 mg/d) and metronidazole (500 mg 3 times/d for 5 days)
Trial: 34255745
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg in week 1, 1000 mg in week 2, 2000 mg daily for weeks 3-12)
Trial: 33541306
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion (TCI) of propofol anesthesia
Trial: 33541306
Drug: Manual infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual infusion (MI) of propofol anesthesia
Trial: 33454272
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg daily for 6 months
Trial: 35635652
Drug: Regorafenib dose-escalation
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib dose-escalation therapy starting at 80 mg/day, escalating to 120 mg/day in Week 2 and 160 mg/day in Week 3 if no severe toxicities observed.
Trial: 35635652
Drug: Regorafenib standard
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib standard therapy (implied as a comparison).
Trial: 32671481
Drug: Denosumab co-administered
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab co-administered with vitamin D (≥ 400 IU/day) and Ca (≥ 600 mg/day)